Form 4: Nephros Director Arthur Amron Reports Equity Acquisition

Director Arthur H. Amron acquired 3,574 shares of Nephros Inc. common stock in lieu of cash board fees.

Summary

• Director Arthur H. Amron received 3,574 shares of common stock as compensation for board service.
• The transaction occurred on May 11, 2026, with the shares issued at a price of $0 per share in lieu of cash fees.
• Following this transaction, the reporting person's direct beneficial ownership of common stock increased to 138,456 shares.
• The filing also details existing derivative holdings, including stock options with exercise prices of $2.14 and $1.47.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices rather than a change in company strategy or financial performance.

Positives

• Director demonstrates alignment with shareholder interests by accepting equity in lieu of cash compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The filing does not provide forward-looking business guidance, as it is a standard disclosure of insider equity transactions.

Industry Context

StockSavvy.ai notes that director equity compensation is a standard corporate governance practice designed to align board incentives with long-term shareholder value, common in the medical device and healthcare technology sectors.

Comparison to Industry Standards

• The issuance of equity in lieu of cash for board service is a standard practice among small-cap healthcare companies to preserve cash reserves.
• The reporting of derivative holdings and vesting schedules aligns with standard SEC disclosure requirements for public company directors.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine compensation-related transaction.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Nephros, NEPH, Form 4, Insider Trading, Director Compensation, Equity Ownership